Skip to main content
Development Programs

Advancing Novel Treatments for Patients with Muscle Disease

Kate Therapeutics has established a pipeline of genetic muscle and cardiac disease indications that can be uniquely addressed by our proprietary capsid and cargo technologies.

  Discovery

     Lead Candidate

 Nonclinical Development

Clinical Development

Lead Candidate

40%

Muscular Dystrophy

Lead Candidate

40%

Cardiomyopathy

Discovery

15%

Myotonic Dystrophy Type 1

Discovery

15%

New Hope for Patients with Muscle and Heart Disease

Kate Therapeutics is a privately-held company with experienced leadership, a world-class scientific advisory team, and leading investor partners.